CRDF Relative Valuation
CRDF's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRDF is overvalued; if below, it's undervalued.
Historical Valuation
Cardiff Oncology Inc (CRDF) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -4.74. The fair price of Cardiff Oncology Inc (CRDF) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 2.16 USD , Cardiff Oncology Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：2.16
Fair
Undervalued
-2.85
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Cardiff Oncology Inc. (CRDF) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-1.49
EV/EBIT
Cardiff Oncology Inc. (CRDF) has a current EV/EBIT of -1.49. The 5-year average EV/EBIT is -2.26. The thresholds are as follows: Strongly Undervalued below -11.70, Undervalued between -11.70 and -6.98, Fairly Valued between 2.46 and -6.98, Overvalued between 2.46 and 7.18, and Strongly Overvalued above 7.18. The current Forward EV/EBIT of -1.49 falls within the Historic Trend Line -Fairly Valued range.
414.32
PS
Cardiff Oncology Inc. (CRDF) has a current PS of 414.32. The 5-year average PS is 695.01. The thresholds are as follows: Strongly Undervalued below -474.42, Undervalued between -474.42 and 110.29, Fairly Valued between 1279.73 and 110.29, Overvalued between 1279.73 and 1864.44, and Strongly Overvalued above 1864.44. The current Forward PS of 414.32 falls within the Historic Trend Line -Fairly Valued range.
-2.51
P/OCF
Cardiff Oncology Inc. (CRDF) has a current P/OCF of -2.51. The 5-year average P/OCF is -3.33. The thresholds are as follows: Strongly Undervalued below -15.27, Undervalued between -15.27 and -9.30, Fairly Valued between 2.64 and -9.30, Overvalued between 2.64 and 8.61, and Strongly Overvalued above 8.61. The current Forward P/OCF of -2.51 falls within the Historic Trend Line -Fairly Valued range.
-2.82
P/FCF
Cardiff Oncology Inc. (CRDF) has a current P/FCF of -2.82. The 5-year average P/FCF is -4.54. The thresholds are as follows: Strongly Undervalued below -15.01, Undervalued between -15.01 and -9.77, Fairly Valued between 0.69 and -9.77, Overvalued between 0.69 and 5.92, and Strongly Overvalued above 5.92. The current Forward P/FCF of -2.82 falls within the Historic Trend Line -Fairly Valued range.
Cardiff Oncology Inc (CRDF) has a current Price-to-Book (P/B) ratio of 2.93. Compared to its 3-year average P/B ratio of 2.00 , the current P/B ratio is approximately 46.31% higher. Relative to its 5-year average P/B ratio of 2.04, the current P/B ratio is about 43.78% higher. Cardiff Oncology Inc (CRDF) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -33.70%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -27.81% , the current FCF yield is about -100.00% lower.
2.97
P/B
Median3y
2.00
Median5y
2.04
-29.46
FCF Yield
Median3y
-33.70
Median5y
-27.81
Competitors Valuation Multiple
The average P/S ratio for CRDF's competitors is 10.76, providing a benchmark for relative valuation. Cardiff Oncology Inc Corp (CRDF) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -27.27%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CRDF decreased by 50.23% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -7.18K to -9.38K.
The secondary factor is the Revenue Growth, contributed -27.27%to the performance.
Overall, the performance of CRDF in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Cardiff Oncology Inc (CRDF) currently overvalued or undervalued?
What is Cardiff Oncology Inc (CRDF) fair value?
How does CRDF's valuation metrics compare to the industry average?
What is the current P/B ratio for Cardiff Oncology Inc (CRDF) as of Dec 05 2025?
What is the current FCF Yield for Cardiff Oncology Inc (CRDF) as of Dec 05 2025?
What is the current Forward P/E ratio for Cardiff Oncology Inc (CRDF) as of Dec 05 2025?